Want to see MLTX full AI Analyst Report?
MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target
676 Followers
MLTX Analyst Ratings
Strong Buy
8Buy1Hold0Sell
Based on 9 analysts giving stock ratings to MoonLake Immunotherapeutics in the past 3 months
MLTX Stock 12 Month Forecast
Average Price Target
$33.00▲(185.47% Upside)Based on 9 Wall Street analysts offering 12 month price targets for MoonLake Immunotherapeutics in the last 3 months. The average price target is $33.00 with a high forecast of $50.00 and a low forecast of $17.00. The average price target represents a 185.47% change from the last price of $11.56.
Past 12 Months12 Month ForecastJan2026Oct2026
High$50.00
Average$33.00
Low$17.00
Highest Price TargetHighest$50.00Average Price Target$33.00Lowest Price TargetLowest$17.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Thomas Smith | Leerink Partners | $30 | buy | 159.52%Upside | Reiterated | 11/05/26 | ||
| Yun Zhong | Wedbush | $34 | buy | 194.12%Upside | Reiterated | 11/04/26 | ||
| Julian Harrison | BTIG | $30 | buy | 159.52%Upside | Reiterated | 11/04/26 | ||
 Unknown AnalystNot Ranked | Guggenheim | $40 | buy | 246.02%Upside | Reiterated | 11/04/26 | ||
| Brian Abrahams | RBC Capital | $17 | hold | 47.06%Upside | Reiterated | 10/27/26 | ||
| Ram Selvaraju | H.C. Wainwright | $50 | buy | 332.53%Upside | Reiterated | 10/05/26 | ||
| Phil Nadeau | TD Cowen | ― | buy | ― | Reiterated | 10/01/26 | ||
| Rami Katkhuda | LifeSci Capital | $33 | buy | 185.47%Upside | Reiterated | 09/30/26 | ||
| Serge Belanger | Needham | $30 | buy | 159.52%Upside | Reiterated | 08/10/26 | ||
| Kaveri Pohlman | Clear Street | $70 | buy | 505.54%Upside | Reiterated | 06/22/26 | ||
| Richard Law CFA | Goldman Sachs | $11→$12 | sell | 3.81%Upside | Reiterated | 05/11/26 | ||
| Andy Chen | Wolfe Research | $12→$24 | buy | 107.61%Upside | Upgraded | 03/23/26 | ||
| Samantha Semenkow | Citi | $6 | sell | -48.10%Downside | Reiterated | 03/20/26 | ||
| Qize Ding | Rothschild & Co Redburn | $12→$40 | buy | 246.02%Upside | Upgraded | 03/19/26 | ||
| Alex Thompson CFA | Stifel Nicolaus | $13→$19 | hold | 64.36%Upside | Reiterated | 03/01/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Thomas SmithLeerink Partners | BuyReiterated$30 | 11/05/26 | 159.52%Upside | ||
| Yun ZhongWedbush | BuyReiterated$34 | 11/04/26 | 194.12%Upside | ||
| Julian HarrisonBTIG | BuyReiterated$30 | 11/04/26 | 159.52%Upside | ||
| Unknown AnalystGuggenheimNot Ranked | BuyReiterated$40 | 11/04/26 | 246.02%Upside | ||
| Brian AbrahamsRBC Capital | HoldReiterated$17 | 10/27/26 | 47.06%Upside | ||
| Ram SelvarajuH.C. Wainwright | BuyReiterated$50 | 10/05/26 | 332.53%Upside | ||
| Phil NadeauTD Cowen | BuyReiterated | 10/01/26 | ― | ||
| Rami KatkhudaLifeSci Capital | BuyReiterated$33 | 09/30/26 | 185.47%Upside | ||
| Serge BelangerNeedham | BuyReiterated$30 | 08/10/26 | 159.52%Upside | ||
| Kaveri PohlmanClear Street | BuyReiterated$70 | 06/22/26 | 505.54%Upside | ||
| Richard Law CFAGoldman Sachs | SellReiterated$11→$12 | 05/11/26 | 3.81%Upside | ||
| Andy ChenWolfe Research | BuyUpgraded$12→$24 | 03/23/26 | 107.61%Upside | ||
| Samantha SemenkowCiti | SellReiterated$6 | 03/20/26 | -48.10%Downside | ||
| Qize DingRothschild & Co Redburn | BuyUpgraded$12→$40 | 03/19/26 | 246.02%Upside | ||
| Alex Thompson CFAStifel Nicolaus | HoldReiterated$13→$19 | 03/01/26 | 64.36%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering MoonLake Immunotherapeutics
3 Months
Success Rate18/27 ratings generated profit
67%
Average Return
+28.52%
Copying Thomas Smith's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +28.52% per trade.
1 Year
Success Rate14/27 ratings generated profit
52%
Average Return
+60.18%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 51.85% of your transactions generating a profit, with an average return of +60.18% per trade.
2 Years
Success Rate10/27 ratings generated profit
37%
Average Return
+35.32%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 37.04% of your transactions generating a profit, with an average return of +35.32% per trade.
MLTX Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 17 | 15 | 8 | 11 | 9 |
| Buy | 4 | 4 | 1 | 2 | 1 |
| Hold | 2 | 1 | 1 | 3 | 2 |
| Sell | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 24 | 20 | 10 | 16 | 12 |
In the current month, MLTX has received 10 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MLTX average Analyst price target in the past 3 months is 33.00.
MLTX Financial Forecast
High$-0.66
Consensus$-0.83
Low$-1.00
MLTX Earnings Forecast
Next quarter’s earnings estimate for MLTX is -$0.83 with a range of -$1.00 to -$0.66. The previous quarter’s EPS was -$0.93. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$0.00
Consensus$0.00
Low$0.00
MLTX Sales Forecast
Next quarter’s sales forecast for MLTX is $0 with a range of $0 to $0. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
MLTX Stock Forecast FAQ
What is MLTX’s average 12-month price target, according to analysts?
Based on analyst ratings, MoonLake Immunotherapeutics’s 12-month average price target is $33.00.
What is MLTX’s upside potential, based on the analysts’ average price target?
MoonLake Immunotherapeutics has 185.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLTX a Buy, Sell or Hold?
MoonLake Immunotherapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is MoonLake Immunotherapeutics’s price target?
The average price target for MoonLake Immunotherapeutics is $33.00. This is based on 9 12-month price targets, issued in the past 3 months. The highest analyst price target is $50.00, the lowest forecast is $17.00. The average price target represents a 185.47% increase from the current price of $11.56.
What do analysts say about MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of MLTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
